CD193. also known as CCR5 (C-C chemokine receptor type 5), is a G protein-coupled receptor expressed on immune cells, including T lymphocytes, macrophages, and dendritic cells. It binds chemokines such as CCL3. CCL4. and CCL5. playing a key role in leukocyte migration and inflammatory responses. CCR5 gained prominence due to its role as a co-receptor for HIV-1 entry into host cells, making it a critical target in HIV research. The discovery that individuals with a natural CCR5Δ32 mutation exhibit resistance to HIV infection spurred therapeutic strategies, including the development of CCR5 antagonists like maraviroc and gene-editing approaches (e.g., CRISPR-based CCR5 knockout).
CD193 antibodies are essential tools for studying CCR5 expression, function, and regulation. They enable applications like flow cytometry, immunohistochemistry, and blocking receptor-ligand interactions in vitro. Beyond HIV, CCR5 is implicated in autoimmune diseases, cancer metastasis, and inflammatory conditions (e.g., rheumatoid arthritis), driving interest in anti-CCR5 therapies. Monoclonal antibodies targeting CCR5 are being explored for modulating immune responses or inhibiting pathological cell migration. However, challenges remain in balancing therapeutic efficacy with potential off-target effects, given CCR5's physiological roles in immune surveillance. Research continues to refine CCR5-targeted biologics and small molecules for precision medicine applications.